Neutralising antibodies and protection from progression to severe COVID-19: A meta-analysis
5 affiliations
- 1Kirby Institute, University of New South Wales, Sydney, Australia
- 2Faculty of Medicine and Health, Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia
- 3School of Mathematics and Statistics, University of New South Wales, Sydney, Australia
- 4Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- 5Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia
Abstract
Background: Vaccine-induced neutralising antibodies are a well-established correlate of protection against acquisition of COVID-19. Vaccine protection from severe COVID-19 remains high, although the role of neutralising antibodies and the contribution of other immune responses to protection from severe outcomes is less clear. Improving understanding of how vaccines prevent severe outcomes is important for future vaccine development. Methods and findings: Here we undertake a systematic search of the literature to obtain estimates of vaccine protection against progression from SARS-CoV-2 infection to severe COVID-19 (hospital or ICU admission). We aggregate results from 25 published clinical studies of vaccine protection from progression to severe outcomes in people with SARS-CoV-2 infection. We match this clinical data to data from 301 studies of post-vaccination neutralisation titres induced by various vaccines against different SARS-CoV-2 variants from the publicly available Stanford University Coronavirus antiviral and resistance database. We then synthesise the data using meta-regression. Neutralising antibody titres were found to be associated with vaccine protection against progression to severe COVID-19 (relative risk (RR) 0.57 per 10-fold increase in GMT, 95% CI [0.51,0.64], p < 0.001). We found that the protection against progression provided by vaccination was higher than that provided by therapeutic passive administration of antibodies, when used to treat individuals with confirmed infection. The main methodological limitations were the fact that neutralisation titres and clinical outcomes were measured in different studies, and the possibility of unmeasured confounding. Conclusions: Together, this work suggests that vaccine-induced neutralising antibodies are correlated with protection from progression to severe COVID-19 and can account for at least a partial mechanistic role in this protection. However, a protection gap remains between the high levels of protection against progressing to severe COVID-19 afforded by vaccination, compared to that afforded by therapeutic administration of antibodies, suggesting other immune responses may also play a role. Why was this study done?: What did the researchers do and find?: What do these findings mean?:
Related
- Structural analysis of the specificity of three neutralising human monoclonal antibodies against poliovirus
- Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial
- Pentasystem embolism associated with transient antiphospholipid antibodies in severe M. pneumoniae pneumonia: a “Dual-Hit” case report and systematic review
- Identifying the shared genetic architecture among severe COVID-19, type 2 diabetes, and obesity using cross-trait meta-analysis
- Comparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study
BibTeX
@article{elias2026neutralising,
title = {{Neutralising antibodies and protection from progression to severe COVID-19: A meta-analysis}},
author = {Karen M. Elias and Ainslie Mitchell and Eva Stadler and Timothy E. Schlub and Shanchita R. Khan and Claire Xue and Stephen J. Kent and Deborah Cromer and Miles P. Davenport and David S. Khoury},
journal = {PLOS Medicine},
year = {2026},
month = sep,
doi = {10.1371/journal.pmed.1005230},
url = {https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005230},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Neutralising antibodies and protection from progression to severe COVID-19: A meta-analysis
AU - Karen M. Elias
AU - Ainslie Mitchell
AU - Eva Stadler
AU - Timothy E. Schlub
AU - Shanchita R. Khan
AU - Claire Xue
AU - Stephen J. Kent
AU - Deborah Cromer
AU - Miles P. Davenport
AU - David S. Khoury
PY - 2026
DA - 2026/09/02
JO - PLOS Medicine
DO - 10.1371/journal.pmed.1005230
UR - https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005230
AB - Background: Vaccine-induced neutralising antibodies are a well-established correlate of protection against acquisition of COVID-19. Vaccine protection from severe COVID-19 remains high, although the role of neutralising antibodies and the contribution of other immune responses to protection from severe outcomes is less clear. Improving understanding of how vaccines prevent severe outcomes is important for future vaccine development. Methods and findings: Here we undertake a systematic search of the literature to obtain estimates of vaccine protection against progression from SARS-CoV-2 infection to severe COVID-19 (hospital or ICU admission). We aggregate results from 25 published clinical studies of vaccine protection from progression to severe outcomes in people with SARS-CoV-2 infection. We match this clinical data to data from 301 studies of post-vaccination neutralisation titres induced by various vaccines against different SARS-CoV-2 variants from the publicly available Stanford University Coronavirus antiviral and resistance database. We then synthesise the data using meta-regression. Neutralising antibody titres were found to be associated with vaccine protection against progression to severe COVID-19 (relative risk (RR) 0.57 per 10-fold increase in GMT, 95% CI [0.51,0.64], p < 0.001). We found that the protection against progression provided by vaccination was higher than that provided by therapeutic passive administration of antibodies, when used to treat individuals with confirmed infection. The main methodological limitations were the fact that neutralisation titres and clinical outcomes were measured in different studies, and the possibility of unmeasured confounding. Conclusions: Together, this work suggests that vaccine-induced neutralising antibodies are correlated with protection from progression to severe COVID-19 and can account for at least a partial mechanistic role in this protection. However, a protection gap remains between the high levels of protection against progressing to severe COVID-19 afforded by vaccination, compared to that afforded by therapeutic administration of antibodies, suggesting other immune responses may also play a role. Why was this study done?: What did the researchers do and find?: What do these findings mean?:
SN - 1549-1676
ER -